MLive1d
What parents of young children should know about RSV, including ‘new armor’
Respiratory syncytial virus, or RSV, typically presents as mild, with symptoms similar to the common cold for adults and ...
Allure on MSN1d
Everything You Need to Know About the 2024 RSV Season
Experts share the official predictions for RSV surge levels in 2024 and 2025, why the levels change each year, and how to ...
FiercePharma1d
Sanofi shrugs off potential RSV competition from Merck as Beyfortus grows sales 382%
On a Friday call with analysts, Sanofi execs pointed to an efficacy edge for its preventive and stressed that more ...
Medpage Today on MSN4d
FDA Expands Approval of RSV Vaccine Abrysvo to Include All At-Risk Adults
The FDA expanded the approval of the bivalent RSV prefusion F (RSVpreF) vaccine (Abrysvo) to include the prevention of lower ...
Laredo Morning Times1h
Laredo Public Health offering free updated COVID-19 vaccines for adults and RSV vaccines
The City of Laredo Public Health Department announced the newly-updated 2024-25 Moderna and Pfizer COVID-19 vaccines are now ...
Seniors Shielded: New RSV Vaccine Shows 80% Effectiveness
Recent findings from a multi-state study reveal that the RSV vaccine is approximately 80% effective in preventing severe ...
fox13now2d
A 'gamechanger' in the fight against RSV
Important information new parents need to know about Respiratory Syncytial Virus, or RSV. It comes around when the weather ...
FiercePharma2d
GSK answers Pfizer's RSV approval with data targeting matching nod in younger adults
“These promising data add to the evidence supporting GSK’s RSV vaccine and could help expand protection to more adults at ...
ENDPOINTS NEWS2d
CDC ad­vi­sors de­cline to rec­om­mend RSV shots to younger at-risk adults, af­firm­ing pri­or guid­ance
The CDC's vaccine policy advisors haven't budged on new RSV guidance, remaining unconvinced that younger adults at higher ...
Just After Pfizer's RSV Vaccine Approval For Younger Adults, GSK Layouts Encouraging Preliminary Data Showing Potential For Use In Larger Population
GSK unveils new Arexvy data showing strong protection in adults 18-49 at risk for RSV. The vaccine could broaden coverage for ...
Study confirms RSV vaccine's protective power for seniors
A global real-world study of the vaccine for respiratory syncytial virus (RSV) finds it offers folks aged 60 and over 80% ...
Free RSV vaccinations slashed hospital presentations of babies and infants
Fewer babies were hospitalised with Respiratory Syncytial Virus (RSV) this year due to the success of free vaccinations in WA ...